TGF-β2 can stimulate angiogenesis by upregulating VEGF-secretion from retinal pigment epithelial (RPE) and endothelial cells 5. Furthermore, it can drive epithelial-to-mesenchymal transformation ...

One of the most promising antiangiogenic treatments is the anti-VEGF monoclonal antibody (mAb) bevacizumab (also known as rhuMAb-VEGF and marketed as Avastin ® by Genentech Inc., South San ...

In Tjitske Zaat and colleagues’ study,1 fewer than 3% of patients in natural menstrual cycles were administered exogenous progesterone for luteal phase support. In their Comment,2 Shari Mackens and ...